Ciliary neurotrophic factor (CNTF) for human retinal degeneration: Phase I trial of CNTF delivered by encapsulated cell intraocular implants
Top Cited Papers
- 27 February 2006
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 103 (10), 3896-3901
- https://doi.org/10.1073/pnas.0600236103
Abstract
Neurotrophic factors are agents with a promising ability to retard progression of neurodegenerative diseases and are effective in slowing photoreceptor degeneration in animal models of retinitis pigmentosa. Here we report a human clinical trial of a neurotrophic factor for retinal neurodegeneration. In this Phase I safety trial, human ciliary neurotrophic factor (CNTF) was delivered by cells transfected with the human CNTF gene and sequestered within capsules that were surgically implanted into the vitreous of the eye. The outer membrane of the encapsulated cell implant is semipermeable to allow CNTF to reach the retina. Ten participants received CNTF implants in one eye. When the implants were removed after 6 months, they contained viable cells with minimal cell loss and gave CNTF output at levels previously shown to be therapeutic for retinal degeneration in rcd1 dogs. Although the trial was not powered to form a judgment as to clinical efficacy, of seven eyes for which visual acuity could be tracked by conventional reading charts, three eyes reached and maintained improved acuities of 10-15 letters, equivalent to two- to three-line improvement on standard Snellen acuity charts. A surgically related choroidal detachment in one eye resulted in a transient acuity decrease that resolved with conservative management. This Phase I trial indicated that CNTF is safe for the human retina even with severely compromised photoreceptors. The approach to delivering therapeutic proteins to degenerating retinas using encapsulated cell implants may have application beyond disease caused by genetic mutations.Keywords
This publication has 49 references indexed in Scilit:
- Expression of CNTF Receptor-α in Chick Violet-Sensitive Cones with Unique Morphologic PropertiesPublished by Association for Research in Vision and Ophthalmology (ARVO) ,2004
- Cloning, Mapping, and Retinal Expression of the Canine Ciliary Neurotrophic Factor Receptor α (CNTFRα)Published by Association for Research in Vision and Ophthalmology (ARVO) ,2003
- Intraocular gene delivery of ciliary neurotrophic factor results in significant loss of retinal function in normal mice and in the Prph2Rd2/Rd2 model of retinal degenerationGene Therapy, 2003
- Long-Term Protection of Retinal Structure but Not Function Using RAAV.CNTF in Animal Models of Retinitis PigmentosaMolecular Therapy, 2001
- Restoration of Cognitive and Motor Functions by Ciliary Neurotrophic Factor in a Primate Model of Huntington's DiseaseHuman Gene Therapy, 2000
- Mammalian-Cell-Produced Neurturin (NTN) Is More Potent Than Purified Escherichia coli-Produced NTNExperimental Neurology, 2000
- Differential regulation of ciliary neurotrophic factor receptor-? expression in all major neuronal cell classes during development of the chick retinaJournal of Comparative Neurology, 1998
- Adenovirus-Mediated Gene Transfer of Ciliary Neurotrophic Factor Can Prevent Photoreceptor Degeneration in the Retinal Degeneration (rd) MouseHuman Gene Therapy, 1997
- Treatment of Amyotrophic Lateral Sclerosis Using a Gene Therapy ApproachEuropean Neurology, 1995
- Survival and development in culture of dissociated parasympathetic neurons from ciliary gangliaDevelopmental Biology, 1976